TITLE

LONG TERM FOLLOW UP OF UC PATIENTS TREATED WITH CYCLOSPORWI--7 YEAR EXPERIENCE

AUTHOR(S)
Campbell, S.; Jewell, D. P.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cyclosporin (CyA) Rx has emerged as an important agent for rescue Rx in acute severe ulcerative colitis. High 1 year relapse rates advocate a limited role of this treatment in light of CyAs s/e profile. Some advocate CyA only as a stopgap to surgical Rx. There are few data available on longer follow up of these patients. These tong term data confirm efficacy and safety of CyA , since 42% patients retain their colon after 80 weeks f/u. Oral CyA appears to be at least as efficacious as intravenous CyA.
ACCESSION #
13218819

 

Related Articles

  • High-Dose Cyclosporine Had No Additional Clinical Benefit over Low-Dose Cyclosporine for Severe Ulcerative Colitis. Van Assche, G.; D'haens, G.; Noman, M. // Annals of Internal Medicine;9/7/2004, Vol. 141 Issue 5, p377 

    This article presents information on benefits of high-dose cyclosporine, over low-dose cyclosporine for the treatment of ulcerative colitis. Cyclosporine is known to be highly effective for patients with severe ulcerative colitis, inducing remission in 50% of patients treated acutely. However,...

  • Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis. Jáuregui-Amézaga, Aránzazu; Ricart, Elena; Panés, Julián // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1467 

    The perception that Crohn's disease is a more severe process than ulcerative colitis, led to the initial development of a majority drugs, and testing of treatment strategies, in the former. In the absence of similar studies in ulcerative colitis, information of Crohn's disease studies may help...

  • Mucosal Healing and anti TNFs in IBD. Assche, Gert van; Vermeire, S�verine; Rutgeerts, Paul // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p227 

    Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohn's disease this concept has only emerged after biological therapies have been evaluated in clinical trials. Systemic steroids don't induce mucosal healing in Crohn's disease, but...

  • Azathioprine Is Useful in Maintaining Long-Term Remission Induced by Intravenous Cyclosporine in Steroid-Refractory Severe Ulcerative Colitis. Fernández-Bañares, F.; Bertrán, X.; Esteve-Comas, M.; Cabré, E.; Menacho, M.; Humbert, P.; Planas, R.; Gassull, M. A. // American Journal of Gastroenterology;Dec1996, Vol. 91 Issue 12, p2498 

    Background/Aim: Therapeutic regimens with intravenous (i.v.) cyclosporine followed by oral cyclosporine maintenance therapy reduce the need for immediate surgery in steroid-refractory severe ulcerative colitis, but the short-term colectomy rate is still as high as 70%. We report our experience...

  • MANAGEMENT OF SPASTIC, IRRITABLE COLON, WITH A NOTE ON ULCERATIVE COLITIS. Rosenblum, Louis A. // American Journal of Gastroenterology;Apr1958, Vol. 29 Issue 4, p407 

    Studies the management of spastic, irritable colon with emphasis on ulcerative colitis. Material and methods; Use of a preparation containing scopolamine methyl bromide, guar gum and a fecal softener; Interpretation of the findings.

  • Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. Sandborn, William J.; Ghosh, Subrata; Panes, Julian; Vranic, Ivana; Su, Chinyu; Rousell, Samantha; Niezychowski, Wojciech // New England Journal of Medicine;8/16/2012, Vol. 367 Issue 7, p616 

    Background: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1...

  • THE USE OF CORTICOTROPIN-ZINC HYDROXIDE IN THE TREATMENT OF ULCERATIVE COLITIS AND OTHER COLONIC DISORDERS. Riese, Jacob A. // American Journal of Gastroenterology;Oct1957, Vol. 28 Issue 4, p452 

    1. The specific etiology of ulcerative colitis remains unknown. Infection and emotion remain prime etiologic theories. 2. The disease is reviewed with regard to pathology, symptomatology, and differential diagnosis. 3. Treatment of ulcerative colitis and other functional colonic disorders with...

  • EXPRESSION OF LECTINS IN NONSPECIFIC ULCERATIVE COLITIS. Markova, A. A.; Kashkina, E. I.; Maslyakova, G. N. // Saratov Journal of Medical Scientific Research / Saratovskii Nau;Oct-Dec2012, Vol. 8 Issue 4, p937 

    Purpose: To analyze the expression of lectins in mucosa of a colon in patients with ulcerative colitis (UC), depending on the duration, severity, location and activity of the inflammatory process. Materials and methods: A total of 48 patients with ulcerative colitis and 15 healthy people have...

  • The role of Asacol in the treatment of patients with ulcerative colitis. Hall, Alex // Gastrointestinal Nursing;Jun2008, Vol. 6 Issue 5, p8 

    Ulcerative colitis (UC) is a chronic inflammatory bowel disease, which typically presents with faecal urgency, diarrhoea (frequently occurring at night and after meals), blood and mucus in stool, and abdominal pain. Initially, UC involves the rectum and spreads proximally in a pattern to involve...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics